Given that the current first- or second-line treatment for patients with stage I–IV pancreatic cancer is Gem plus Ptx, we sought to assess the effect of a PRMT5 pharmacologic inhibitor in combination with Gem plus Ptx. This evidence concerns the gene PRMT5 and familial pancreatic carcinoma.